Nation-wide registry for chronic hepatitis C patients in Taiwan
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
This study is creating a nationwide database to see how well new hepatitis C treatments work and how safe they are for patients in Taiwan.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150000 (estimated) |
| Sex | All |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT03200379 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a nationwide registry to evaluate the efficacy, safety, and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals (DAAs) in Taiwan. It will collect data from both academic and community practices to assess real-world effectiveness and identify clinical gaps in treatment guidelines and management of adverse events. The registry will be supported by the National Health Insurance Administration (NHIA) to ensure comprehensive data collection and analysis. By creating this database, the study seeks to provide valuable insights into the treatment of hepatitis C in the Taiwanese population.
Who should consider this trial
Good fit: Ideal candidates for this study are chronic hepatitis C patients who are currently being treated with directly acting antivirals and are willing to participate.
Not a fit: Patients who are unwilling to participate or do not provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and better health outcomes for chronic hepatitis C patients.
How similar studies have performed: Other studies have shown success with similar registry approaches in evaluating treatment outcomes for chronic diseases, indicating potential for valuable insights from this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Patients who are treated with DAA and have willingness to participate in this registry. Exclusion Criteria: Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.
Where this trial is running
Kaohsiung City
- HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan — Kaohsiung City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Ming-Lung Yu, MD., PhD — HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- Study coordinator: Ming-Lung Yu, MD., PhD
- Email: fish6069@gmail.com
- Phone: 88673121101
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.